CD20 Monoclonal Antibody
Oct 27, 2025
Roche’s GAZYVA Extends Indications Into Lupus, Strengthening Immunology Pipeline
As the lupus treatment landscape undergoes major changes, Roche is entering the US lupus nephritis market with a fresh FDA approval for its long-standing blood cancer drug, GAZYVA. On October 20, 2025, Roche’s Genentech division announced that the FDA had approved GAZYVA (obinutuzumab) for use in adults with active...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
